| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Magnesium Aspartate Dihydrate |
| Brand | Magnaspartate® |
| Indication | For the treatment and prevention of magnesium deficiency as diagnosed by a doctor. Magnaspartate is indicated in adults, children and adolescents aged from 2 years. |
| Assessment Process | |
| Rapid review commissioned | 27/02/2019 |
| Rapid review completed | 14/05/2019 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that magnesium aspartate dihydrate not be considered for reimbursement at the submitted price. |
This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.